BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zanzalintinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zanzalintinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06568562-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06568562)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: XL092 in Patients With Metasta
 tic Castration-Resistant Prostate Cancer\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalin
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06568562
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: Study o
 f XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic N
 on-Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5678673
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698250-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06698250)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib (XL-092) Plus Du
 rvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBI
 A)\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06698250
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05176483-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT05176483)
DESCRIPTION:Zanzalintinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents 
 in Participants With Solid Tumors\nEstimated primary completion: 31 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051
 76483
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952010-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT06952010)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: A Study of XB628 Alone and in 
 Combination With Zanzalintinib in Participants With Recurrent Advanced or 
 Metastatic Solid Tumors\nEstimated primary completion: 31 May 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06952010
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06912087-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270605
DTEND;VALUE=DATE:20270606
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT06912087)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: Dose Finding Study of Zanzalin
 tinib With Pembrolizumab and Cetuximab in Head and Neck SCC\nEstimated pri
 mary completion: 5 June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06912087
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511504-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07511504)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Y-90 Radioembolization\, Durva
 lumab\, Tremelimumab\, and Zanzalintinib for the Treatment of Unresectable
  and Locally-Advanced Hepatocellular Carcinoma\nEstimated primary completi
 on: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/za
 nzalintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07511504
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863311-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06863311)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Pa
 tients Who Progress on Adjuvant Therapy in Clear Cell RCC\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06863311
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226063-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07226063)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Maintenance Zanzalintinib and 
 Durvalumab in Participants With Advanced Hepatocellular Cancer\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07226063
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428616-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07428616)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: A Study of Zanzalintinib in Pa
 rticipants With Recurrent or Progressive Meningioma\nEstimated primary com
 pletion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07428616
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959511-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06959511)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib for the Treatmen
 t of Advanced Thyroid Cancer Before Surgery\nEstimated primary completion:
  1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzal
 intinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06959511
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902376-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT06902376)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: XL092 and Cemiplimab in BRAF W
 T Thyroid Cancer\nEstimated primary completion: 31 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06902376
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484139-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07484139)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: H&N NEO-COMBAT XL: Neoadjuvant
  XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resecta
 ble\, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)\nEstimated 
 primary completion: May 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07484139
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794229-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06794229)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Adva
 nced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non
 -measurable Metastasis\nEstimated primary completion: 6 June 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06794229
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Zanzalintinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Z
 anzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Sq
 uamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1
 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalin
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845786
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07578025-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280624
DTEND;VALUE=DATE:20280625
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07578025)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Can
 cer After Progression on Immunotherapy\nEstimated primary completion: 24 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7578025
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218666-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07218666)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib in Men With Aggr
 essive Variant Prostate Cancer\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07218666
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571734-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06571734)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: XL092 (Zanzalintinib) for the 
 Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma\, Bon
 e Sarcoma or Translocation-associated Soft Tissue Sarcoma\nEstimated prima
 ry completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06571734
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527169-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07527169)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: A Phase 2 Study Of Zanzalintin
 ib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma\nEsti
 mated primary completion: 1 July 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07527169
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773454-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT07773454)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: Study of Zanzalintinib in Chil
 dren and Adolescents With Relapsed or Refractory Solid Tumors\nEstimated p
 rimary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07773454
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06082167-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zanzalintinib: Phase 2/3 readout est. (NCT06082167)
DESCRIPTION:Zanzalintinib\, phase 2/3.\nStudy: Study of Zanzalintinib (XL09
 2) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurr
 ent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated primary
  completion: August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06082167
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677579-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07677579)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: NIMBLE-CRC: NeoImmunoModulatio
 n Before Leveraging Excision in Colorectal Rectal Cancer\nEstimated primar
 y completion: 30 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07677579
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623460-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07623460)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib Efficacy Post Pl
 uvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate C
 ancer\nEstimated primary completion: September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07623460
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959641-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280911
DTEND;VALUE=DATE:20280912
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06959641)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: XL092 for the Treatment of Loc
 ally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid 
 Cancer\nEstimated primary completion: 11 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06959641
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691476-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07691476)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and P
 embrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma\n
 Estimated primary completion: 31 October 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07691476
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283731-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07283731)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Phase 2 Trial of Zanzalintinib
  and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue S
 arcoma\nEstimated primary completion: 1 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07283731
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878689-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanzalintinib: Phase 1/2 readout est. (NCT07878689)
DESCRIPTION:Zanzalintinib\, phase 1/2.\nStudy: Study of Tegavivint Plus Zan
 zalintinib in Patients With Advanced Hepatocellular Carcinoma\nEstimated p
 rimary completion: 1 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07878689
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042919-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290304
DTEND;VALUE=DATE:20290305
SUMMARY:Zanzalintinib: Phase 1/2 readout est. (NCT07042919)
DESCRIPTION:Zanzalintinib\, phase 1/2.\nStudy: Zanzalintinib in Second Line
  and Beyond for the Treatment of Advanced Liver Cancer\nEstimated primary 
 completion: 4 March 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07042919
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682675-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07682675)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Study to Evaluate the Efficacy
  of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cysti
 c Carcinomas of the Head and Neck\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07682675
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043608-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07043608)
DESCRIPTION:Zanzalintinib\, phase 2\, Clear Cell Renal Cell Carcinoma.\nStu
 dy: Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone
  Metastases\nEstimated primary completion: 30 April 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07043608
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608718-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07608718)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Phase II Trial of Zanzalitinib
  in Patients With Metastatic Castration Resistant Prostate Cancer\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07608718
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943755-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Zanzalintinib: Phase 2/3 readout est. (NCT06943755)
DESCRIPTION:Zanzalintinib\, phase 2/3.\nStudy: Zanzalintinib Versus Everoli
 mus in Participants With Locally Advanced or Metastatic Neuroendocrine Tum
 ors\nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06943755
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193550-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07193550)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: A Phase 2 Trial of Zanzalintin
 ib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)\nEstimated primary compl
 etion: 31 October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07193550
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795009-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT06795009)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: Zanzalintinib in Combination W
 ith Paclitaxel in Recurrent High Grade Uterine Cancer\nEstimated primary c
 ompletion: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06795009
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06937866-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Zanzalintinib: Phase 1/2 readout est. (NCT06937866)
DESCRIPTION:Zanzalintinib\, phase 1/2.\nStudy: Maintenance Zanzalintinib Wi
 th Etoposide After HDCT in GCT\nEstimated primary completion: March 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06937866
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750158-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300405
DTEND;VALUE=DATE:20300406
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07750158)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Zanzalinti
 nib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa 
 in Participants With Colorectal Cancer With Molecular Residual Disease\nEs
 timated primary completion: 5 April 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07750158
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Zanzalintinib\, phase 3\, Colorectal Cancer.\nStudy: Long-Term 
 Extension Study for Participants Previously Enrolled in an Exelixis-Sponso
 red Study\nEstimated primary completion: 31 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470489-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07470489)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib Plus Cemiplimab 
 for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer\nEstimated p
 rimary completion: 1 September 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07470489
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489495-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20301127
DTEND;VALUE=DATE:20301128
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07489495)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: A Clini
 cal Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal C
 ell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)\nEstimated primary 
 completion: 27 November 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07489495
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07714551-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07714551)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib in Unresectable 
 and Progressive MPGGs\nEstimated primary completion: 1 January 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07714551
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06957431-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Zanzalintinib: Phase 1 readout est. (NCT06957431)
DESCRIPTION:Zanzalintinib\, phase 1.\nStudy: Zanzalintinib Combined With Er
 ibulin in Advanced Liposarcoma and Leiomyosarcoma\nEstimated primary compl
 etion: 31 May 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 anzalintinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06957431
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049926-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20311026
DTEND;VALUE=DATE:20311027
SUMMARY:Zanzalintinib: Phase 1/2 readout est. (NCT07049926)
DESCRIPTION:Zanzalintinib\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Subst
 udy 03C: A Study of Combination Therapies in Participants With Renal Cell 
 Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-
 3475-03C/KEYMAKER-U03)\nEstimated primary completion: 26 October 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/zanzalintinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07049926
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227402-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20320227
DTEND;VALUE=DATE:20320228
SUMMARY:Zanzalintinib: Phase 3 readout est. (NCT07227402)
DESCRIPTION:Zanzalintinib\, phase 3\, Renal Cell Carcinoma.\nStudy: A Clini
 cal Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney 
 Cancer Following Adjuvant Therapy (MK-6482-033)\nEstimated primary complet
 ion: 27 February 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zanzalintinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07227402
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926634-2819@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT06926634)
DESCRIPTION:Zanzalintinib\, phase 2.\nStudy: Zanzalintinib Maintenance in P
 atients With High Grade Neuroendocrine Neoplasms (HG-NENs)\nEstimated prim
 ary completion: 31 December 2034. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zanzalintinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06926634
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
